Cuprina Holdings (Cayman) Limited
CUPR evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CUPR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CUPR
Cuprina Holdings (Cayman) Limited (CUPR) is a commercial-stage medical technology company focused on chronic wound care, with one fully commercialized product line (MEDIFLY) and a pipeline of early-stage products. The company has minimal revenue and recurring net losses, and its future depends on regulatory approvals and successful commercialization of pipeline candidates.
Key risk: Regulatory approval risk
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Dec 31, 2025.
Cuprina Holdings (Cayman) Limited (CUPR) is a commercial-stage medical technology company focused on chronic wound care, with one fully commercialized product line (MEDIFLY) and a pipeline of early-stage products. The company has minimal revenue and recurring net losses, and its future depends on regulatory approvals and successful commercialization of pipeline candidates.
- As of December 31, 2025, Cuprina had fully commercialized one distinct line of chronic wound care products, its MEDIFLY products, which accounted for 78.4%, 71.2%, and 88.6% of revenue for the years ended December 31, 2023, 2024, and 2025, respectively [sec · filed 2026-04-27].
- Revenue was S$49,894 (US$38,789) for the year ended December 31, 2025, with a net loss of S$4,673,447 (US$3,633,248) for the same period [sec · filed 2026-04-27].
- As of December 31, 2025, the company had 10 full-time employees and an R&D team of two full-time members [sec · filed 2026-04-27].
- Cash and equivalents were $2.4M as of December 31, 2025, with shareholders' equity of -$1.8M and total debt of $0.2M [latest reported financials].
- The company relies on FDA 510(k) clearance for its chronic wound care products and faces risks related to regulatory approval, commercialization, and dependence on third-party agreements [sec · filed 2026-04-27].
What works
- Cuprina has a commercialized product line (MEDIFLY) that has generated consistent, albeit minimal, revenue over the past three years, indicating some market presence [sec · filed 2026-04-27].
- The company describes its product portfolio as innovative and differentiating from competitors, which may provide a competitive advantage if pipeline products reach market [sec · filed 2026-04-27].
- Cuprina engages with a variety of sales channels, including distributors, retail chains, e-commerce, and social media, which could support future product adoption [sec · filed 2026-04-27].
What to weigh
- Cuprina has minimal revenue (S$49,894 in 2025) and has recorded net losses for three consecutive years, with accumulated losses growing (net loss of S$4.7M in 2025) [sec · filed 2026-04-27].
- The company has a very small workforce (10 employees as of December 31, 2025) and limited R&D capacity (2 team members), which may constrain product development and commercialization efforts [sec · filed 2026-04-27].
- Cuprina's pipeline products are in early developmental stages and face significant risks, including failure to meet safety/efficacy standards, obtain regulatory approval, or achieve market acceptance [sec · filed 2026-04-27].
- The company is heavily dependent on third-party agreements for development and sales, and termination of those agreements could materially harm its business [sec · filed 2026-04-27].
From the filings
Quoted directly from source documents.
Cuprina's revenue is minimal and declining, with net losses increasing.
“For the years ended December 31, 2023, 2024, and 2025, our revenue amounted to S$100,773, S$48,321 and S$49,894 (US$38,789), respectively, while we recorded net loss of S$1,119,555, S$1,560,535 and S$4,673,447 (US$3,633,248), respectively, for the same periods.”
SEC filings · April 27, 2026
Risks & what to watch (4)›
Key risks
- Regulatory approval risk — Pipeline products may fail to obtain FDA 510(k) clearance or foreign approvals, delaying or preventing commercialization [sec · filed 2026-04-27].
- Commercialization risk — Even if approved, products may not gain market acceptance due to competition, pricing, or lack of adoption [sec · filed 2026-04-27].
- Financial sustainability risk — Minimal revenue and recurring net losses raise going-concern questions; cash of $2.4M may be insufficient for long-term operations [latest reported financials].
- Dependence on third parties — Development and sales rely on third-party agreements; termination could materially harm business [sec · filed 2026-04-27].
What to watch
- Progress of pipeline products through preclinical and clinical testing, particularly safety and efficacy results [sec · filed 2026-04-27].
- Any updates on FDA 510(k) clearance or foreign regulatory approvals for chronic wound care products [sec · filed 2026-04-27].
- Changes in cash position, revenue, and net loss in future quarterly or annual filings [latest reported financials].
- Ability to maintain or expand relationships with distributors, retailers, and e-commerce platforms [sec · filed 2026-04-27].
Sources: SEC filings · Generated August 18, 2026 · How we verify sources →
Run Cuprina Holdings (Cayman) Limited through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Cuprina Holdings (Cayman) Limited facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
1.4 months
D/E 0.68 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
2
Total value held
$21K
| Holder | Shares | Value |
|---|---|---|
| citadel advisors llc | 37,281 | $11K |
| xtx topco ltd | 35,457 | $10K |
Short Interest
as of May 20, 2026- % of float
- 1.3%
- Days to cover
- 0.0
- Shares short
- 94,217
- Daily short volume (May 12, 2026)
- 17.9%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CUPR short interestFrequently asked questions
What is the AI investment thesis for Cuprina Holdings (Cayman) Limited?
Cuprina Holdings (Cayman) Limited (CUPR) is a commercial-stage medical technology company focused on chronic wound care, with one fully commercialized product line (MEDIFLY) and a pipeline of early-stage products. The company has minimal revenue and recurring net losses, and its future depends on regulatory approvals and successful commercialization of pipeline candidates.
Who is the CEO of Cuprina Holdings (Cayman) Limited?
Mr. Yong Qi Quek is the chief executive officer of Cuprina Holdings (Cayman) Limited (CUPR).
Where is Cuprina Holdings (Cayman) Limited headquartered?
Cuprina Holdings (Cayman) Limited (CUPR) is headquartered in Singapore, Singapore.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.